Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CRCP encodes a membrane protein that functions as part of a receptor complex for a small neuropeptide that increases intracellular cAMP levels.
Showing 10 out of 18 products:
CGRP (show CALCA Antibodies) can inhibit microglia activation in vivo in EAE. CGRP (show CALCA Antibodies) and its receptor may represent novel protective factors in EAE.
CGRP-receptor component protein has been found to interact only with calcitonin (show CALCA Antibodies)-like receptor and represents a novel neuroendocrine regulatory step in calcitonin gene-related peptide (show CALCA Antibodies) signaling.
The mouse cDNA for calcitonin receptor-like receptor (CRLR (show CALCRL Antibodies)) was cloned. The signal transduction mechanism through the CGRP (show CALCA Antibodies) receptor was studied. mCRLR is a 462-amino acid G-protein-coupled heptahelical receptor (show AGTR1 Antibodies).
data reinforce and clarify our understanding of CGRP (show S100A12 Antibodies) receptor localization, and provide evidence that antagonist antibodies bind to target sites in the trigeminovascular system of primates that are involved in the pathology of migraine
CGRP (show S100A12 Antibodies) family of receptors displays both ligand- and RAMP-dependent signaling bias among the Galphas (show GNAS Antibodies), Galphai, and Galphaq (show GNAQ Antibodies)/11 pathways.
In this review, the influence of the CGRP (show S100A12 Antibodies) family peptides in reproduction and pregnancy is explored and discussed.
This study demonstrates the detailed expression of CGRP (show S100A12 Antibodies) and its receptor components within spinal trigeminal nucleus in the brainstem and in the spinal cord at C1-level
The extracellular protein domains corresponding to residues 23-133 of calcitonin receptor-like receptor (show CALCRL Antibodies) and residues 26-117 of receptor activity-modifying protein 1 (RAMP1 (show RAMP1 Antibodies)) are shown to be sufficient for formation of a stable, folded monodisperse complex.
Data describe the role of residues 23-60 of the calcitonin receptor-like receptor (show CALCRL Antibodies) in binding with interaction sites within the N-terminus of the calcitonin gene-related peptide (show CALCA Antibodies) receptor.
Expression of CGRP-RCP was detected in CD34 (show CD34 Antibodies)+ cells and also in some mature granulocyte samples, providing evidence that CGRP-RCP may be regulated independently of RAMP1 (show RAMP1 Antibodies) and CRLR (show CALCRL Antibodies) in hematopoietic cells.
human CGRP-RCP is the genuine orthologue of C17. CGRP-RCP was found to functionally replace C17 in Deltarpc17 yeast cells; CGRP-RCP was identified in a purified human Pol III preparation.
inhibition of ACE (show ACE Antibodies) seems to augment CGRP (show S100A12 Antibodies) catabolism.
Increased mRNA expression CGRP-RCP in gravid myometrium supports the possibility of involvement of CGRP (show S100A12 Antibodies) in the control of myometrial contractility.
This gene encodes a membrane protein that functions as part of a receptor complex for a small neuropeptide that increases intracellular cAMP levels. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
calcitonin gene-related peptide-receptor component protein
, DNA-directed RNA polymerase III subunit RPC9
, CGRP-receptor component protein
, RNA polymerase III subunit C9